Prediction of the risk of myocardial infarction development in patients with peripheral atherosclerosis in the long term


DOI: https://dx.doi.org/10.18565/therapy.2022.5.39-46

Kobzeva N.D., Martynov A.I., Terentiev V.P.

1) Rostov State Medical University of the Ministry of Healthcare of Russia, Rostov-on-Don; 2) A.I. Yevdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia
Abstract. Risk stratification in patients with peripheral atherosclerosis is extremely important, since it determines the direction of management tactics for patients with high and very high cardiovascular risk.
Aim: development of a method for predicting the development of myocardial infarction (MI) in patients with peripheral atherosclerosis in the long term.
Material and methods. The study included 519 patients (mean age 60.0±8,7 years) with atherosclerotic lesions in various vascular regions. All patients underwent standard biochemical studies and a set of instrumental studies. The period of prospective follow-up was 36 months.
Results. In the course of binary logistic regression analysis, combinations of factors were identified that demonstrated their statistical significance in relation to the risk of developing MI in the long-term period, namely, «duration of diabetes mellitus, years + history of MI» (p=0,030), «chronic heart failure + duration of diabetes mellitus, years» (p=0,049), «ejection fraction value, % + history of MI» (p=0,0006), «number of affected vascular beds + chronic heart failure» (p <0,001), «number affected vascular pools + MI in anamnesis» (p <0,001) in relation to the point of fatal and non-fatal MI.
Conclusions. Nomograms have been developed for assessing the risk of MI in the long-term period, which can be used in real clinical practice.

Literature


1. Драпкина О.М., Концевая А.В., Калинина А.М. с соавт. Профилактика хронических неинфекционных заболеваний в Российской Федерации. Национальное руководство. 2022. Кардиоваскулярная терапия и профилактика. 2022; 4: 3235. [Drapkina O.M., Kontsevaya A.V., Kalinina A.M. et al. 2022 Prevention of chronic non-communicable diseases in the Russian Federation. National guidelines. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2022; 4: 3235 (In Russ.)].https://dx.doi.org/10.15829/1728-8800-2022-3235. EDN: DNBVAT.


2. Gutierrez J.A., Mulder H., Jones W.S. et al. Polyvascular disease and risk of major adverse cardiovascular events in peripheral artery disease: A secondary analysis of the EUCLID Trial. JAMA Netw Open. 2018; 1(7): e185239.https://dx.doi.org/10.1001/jamanetworkopen.2018.5239.


3. Amer M.S., Tawfik H.M., Elmoteleb A.M. et al. Correlation between ankle brachial index and coro- nary artery disease severity in elderly Egyptians. Angiology. 2014; 65(10): 891–95. https://dx.doi.org/10.1177/ 0003319713510594.


4. Седых Д.Ю., Казанцев А.Н., Тарасов Р.С. с соавт. Предикторы прогрессирования мультифокального атеросклероза у пациентов, перенесших инфаркт миокарда. Кардиология. 2019; 5: 36–44. [Sedykh D.Yu., Kazantsev A.N., Tarasov R.S. et al. Predictors of progressive course of multifocal atherosclerosis in patients with myocardial infarction. Kardiologiya = Cardiology. 2019; 5: 36–44 (In Russ.)]. https://dx.doi.org/10.18087/cardio.2019.5.10257. EDN: WSBXWJ.


5. DeFilippis A.P., Trainor P.J., Thanassoulis G. et al. Atherothrombotic factors and atherosclerotic cardiovascular events: The multiethnic study of atherosclerosis. Eur Heart J. 2022; 43(10): 971–81. https://dx.doi.org/10.1093/eurheartj/ehab600.


6. Gragnano F., Calabro P. Do we need a redefinition of the cardiovascular risk categories used in the 2019 ESC/EAS guidelines on dyslipidaemias? Eur Heart J. 2020; 41(24): 2332. https://dx.doi.org/10.1093/eurheartj/ehz940.


7. Кобзева Н.Д. Особенности влияния атеросклеротического поражения различных сосудистых бассейнов на риск развития фатальных и нефатальных событий в отдаленном периоде. Терапия. 2021; 8: 70–75. [Kobzeva N.D. Features of the influence of atherosclerotic damage of various vascular basins on the risk of development of fatal and non-fatal events in a long period. Terapiya = Therapy. 2021; 8: 70–75 (In Russ.)]. https://dx.doi.org/10.18565/therapy.2021.8.70-75. EDN: UXEEAH.


8. ukema J.W., Szarek M., Zijlstra L.E. et al.; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab in patients with polyvascular disease and recent acute coronary syndrome: ODYSSEY OUTCOMES trial. J Am Coll Cardiol. 2019; 74(9): 1167–76. https://dx.doi.org/10.1016/j.jacc.2019.03.013.


9. Stabile E., Giugliano G., Cremonesi A. et al. Impact on outcome of different types of carotid stent: Results from the European Registry of Carotid Artery Stenting. EuroIntervention. 2016; 12(2): e265–70. https://dx.doi.org/10.4244/EIJV12I2A41.


10. Takahara M., Iida O., Kohsaka S. et al; J-EVT and J-PCI investigators. Diabetes mellitus and other cardiovascular risk factors in lower-extremity peripheral artery disease versus coronary artery disease: An analysis of 1,121,359 cases from the nationwide databases. Cardiovasc Diabetol. 2019; 18(1): 155. https://dx.doi.org/10.1186/s12933-019-0955-5.


11. Lamina C., Meisinger C., Heid I. M. et al. Association of ankle-brachial index and plaques in the carotid and femoral arteries with cardiovascular events and total mortality in a population-based study with 13 years of follow-up. Eur Heart J. 2006; 27(21): 2580–87. https://dx.doi.org/10.1093/eurheartj/ehl228.


About the Autors


Natalia D. Kobzeva, PhD in Medicine, associate professor of the Department of internal diseases No. 1, Rostov State Medical University of the Ministry of Healthcare of Russia. Address: 344022, Rostov-on-Don, 29 Nakhichevansky Lane. E-mail: kobzeva.nataliya1@gmail.com. ORCID: https://orcid.org/0000-0002-3390-2452
Anatoly I. Martynov, Dr. med. habil., academician of RAS, professor of the Department of hospital therapy No. 1, A.I. Yevdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia. Address: 127473, Moscow, 20/1 Delegatskaya Str. ORCID: 0000-0002-0783-488X
Vladimir P. Terentiev, Dr. med. habil., professor, head of the Department of internal diseases No. 1, Rostov State Medical University of the Ministry of Healthcare of Russia. Address: 344022, Rostov-on-Don, 29 Nakhichevansky Lane. E-mail: vpterentev@mail.ru. ORCID: https://orcid.org/0000-0003-3607-5832


Similar Articles


Бионика Медиа